Crinetics Pharmaceuticals CRNX 深 滬
已收盤 12-24 16:00:00 美东时间
48.71
-0.160
-0.33%
華盛通- 最 高49.61
- 今 開48.91
- 成交量 30.11万股
- 最 低 48.515
- 昨 收 48.87
- 總市值 45.87亿
- 52周最高 53.55
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 24.10
- 委 比 82.12%
- 總股本 9417.60万
- 歷史最高 62.53
- 量 比 0.23
- 振 幅 2.24%
- 歷史最低 10.63
- 每 手 1
- 風險率 6.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
12-19 20:55
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals' CEO, Scott Struthers, will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026. A live audio webcast and archived version will be available via the provided links. Crinetics focuses on treating endocrine diseases and tumors, with its lead product PALSONIFY™ for acromegaly and other investigational therapies in development. Investors and media can contact the listed representatives for further inqui...
12-18 21:05
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
<p>Crinetics Pharmaceuticals启动CALM-CAH 3期临床试验，评估atumelnant治疗经典型肾上腺增生症的效果。该药物在2期研究中已显示积极结果，可迅速降低疾病生物标志物水平。3期试验将评估其对雄激素和皮质醇水平的调节能力，为疾病控制设新标准。atumelnant是首个进入后期临床开发的ACTH受体拮抗剂，Crinetics已获FDA孤儿药指定。更多详情请访问<a href="https://clinicaltrials.gov/study/NCT07159841">临床试验官网</a>。</p>
12-11 21:05
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals granted stock options and RSUs to 9 new employees under the 2021 Inducement Plan. The stock options cover 39,575 shares with a $48.06 exercise price, vesting over four years, while the RSUs (26,525 units) vest annually over four years, both contingent on continued employment. The company, focused on endocrine disease treatments, recently announced its lead product PALSONIFY™ for acromegaly and has a pipeline addressing v...
12-10 21:34
Crinetics Announces First Patient Dosed In Phase 1/2 Study Evaluating CRN09682 In Patients With Advanced SST2-Positive Neuroendocrine Tumors And Other SST2-Expressing Solid Tumors
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2
12-03 21:07
Crinetics Randomizes First Patient In Phase 3 CAREFNDR Trial Of Oral Paltusotine For Carcinoid Syndrome
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov.
11-21 05:11
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals granted stock options for 37,675 shares and 25,300 RSUs to 11 new non-executive employees under the 2021 Inducement Plan. The stock options have an exercise price of $41.45 per share, vesting over four years, with 25% on the first anniversary and monthly thereafter. RSUs vest annually over four years. Both awards are subject to continued employment, aligning with Nasdaq Listing Rule 5635(c)(4).
11-10 21:28
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Crinetics Pharmaceuticals Reports Positive Launch and Financials
Crinetics Pharma ( ($CRNX) ) has released its Q3 earnings. Here is a breakdown ...
11-07 13:55
